OLIGOPELVIS 2 Shows Acceptable Toxicity With Salvage Nodal Radiotherapy
The phase III OLIGOPELVIS 2–GETUG P12 trial provides early safety data for salvage elective nodal radiotherapy combined with intermittent androgen deprivation therapy in patients with oligorecurrent…
Read the full articleYou might also wanna read
La inmunoterapia posquirúrgica ayudó a las personas con cáncer de vejiga de riesgo alto a vivir sin cáncer por más tiempo
En un estudio del NCI, se observó que administrar pembrolizumab a los pacientes después de la cirugía para el cáncer de vejiga con invasión
PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer
Conditions : Oligoprogressive Prostate Cancer; Metastatic Prostate Cancer Interventions : Radiation: Progression-Directed Radiotherapy Spons
Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer
Conditions : Prostate Cancer; Metastatic Prostate Cancer; Oligometastatic Prostate Cancer; Synchronous Oligometastatic Prostate Cancer Inter
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
Conditions : Ovarian Neoplasms Interventions : Drug: Mocertatug rezetecan (Mo-Rez); Drug: Carboplatin; Drug: Paclitaxel; Drug: Gemcitabine;
Experimental Novartis radiopharma drug shows promise in early study
Experimental Novartis radiopharma drug shows promise in early study reut.rs/434TIoY
Una combinación de medicamentos dirigidos produce remisiones duraderas en las personas con linfoma de células B de crecimiento rápido resistente al tratamiento
Los tumores de más de la mitad de los participantes que recibieron tratamiento con venetoclax, ibrutinib, prednisona, obinutuzumab y lenalid
Comments
Sign in to join the conversation.
No comments yet. Be the first.